Medindia

X

Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio

Monday, November 26, 2007 General News J E 4
Advertisement
CHICAGO, Nov. 25 Siemens Medical Solutions(www.usa.siemens.com/medical) introduces the latest innovations to its breastcare portfolio, designed to help detect, diagnose and treat breast cancerearlier, faster, and with greater precision, at the 93rd Scientific Assemblyand Annual Meeting of the Radiological Society of North America (RSNA) fromNov. 25 to 30 at McCormick Place (Booth #7713, Hall B). As the world's firstfull-service diagnostics company, Siemens is showcasing its uniquecapabilities to provide solutions that address each step of breast care.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

"Siemens continues to raise the bar for innovation by offering acomprehensive range of breast care solutions, as evidenced by the leading-edgetechnologies on display at this year's RSNA," said Erich R. Reinhardt, Ph.D.,member of the Managing Board of Siemens AG and president and CEO of SiemensMedical Solutions. "Siemens is enabling facilities to provide quality caretailored to the individual patient's needs and optimize productivity,workflow, and, ultimately, financial performance."

By combining advanced imaging, laboratory diagnostics, and informationtechnologies, Siemens helps physicians not only detect, diagnose and treatbreast cancer in its earliest, most treatable stages, but also provides themwith comprehensive after-care solutions. This holistic approach enablesshorter exams, streamlined workflow, and improved patient outcomes. With themovement toward a multimodality approach to breast care, imaging technologiessuch as ultrasound and magnetic resonance imaging (MRI) are playing anincreasing role in all stages of breast care. At RSNA, Siemens is showcasingits latest advancements in breast ultrasound and MRI, as well as the nextgeneration of digital mammography systems and immunodiagnostic testing.

Digital Mammography Simplified: MAMMOMAT Novation S

Introducing MAMMOMAT(R) Novation S, a cost-effective solution forfacilities that are making the transition to digital breast imaging but do nothave the need for the advanced functionality of state-of-the-art systems. TheMAMMOMAT Novation S optimizes workflow, utilizes the latest full-fieldamorphous Selenium (aSe) detectors and features Tungsten/Rhodium (W/Rh) X-raytechnology, which reduces dose.

Ultrasound Technology Helping to Reduce Biopsies and Image Dense Breasts

Siemens' breakthrough breast ultrasound technology, eSie Touch(TM)elasticity imaging, has shown promise in reducing reliance on invasive breastbiopsy procedures. According to published research as many as 80 percent ofbiopsied breast lesions are found to be benign. Elasticity imaging measuresthe mechanical properties of tissue providing additional information forenhanced diagnostic decision-making. Clinical studies indicate that elasticityimaging has the potential to increase specificity in the evaluation anddetermination of focal breast lesions. Elasticity imaging has recently beenrecognized as the "Best New Product of the Year" by the Stevie Awards forWomen in Business -- an international competition recognizing theaccomplishments of outstanding business women as well as products, servicesand innovations introduced to the marketplace by or for women.

In addition, the U-Systems SomoVu(TM) Automated Breast Ultrasound System*provides a fast, cost-effective, patient-friendly solution, especially when itcomes to overcoming the challenges posed in imaging and screening of densebreast tissue. Unlike conventional ultrasound acquisition techniques where theuser moves a transducer over the breast, automated breast scanning (ABS)technology is a single-sweep, automated acquisition technique that producesstandardized, reproducible three-dimensional ultrasound images for improveddiagnostic confidence.

Advances in MRI Breast Spectroscopy

A recent study published in Radiol
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Schering-Plough Announces Asenapine NDA Accepted f...
S
NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue ...